Vascular endothelial growth factor gene transfer for diabetic polyneuropathy

Annals of Neurology

Volumn 65, Issue 4, 2009, Pages 362-364

  Kessler, John A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA; LIPOSOME; NEUROTROPHIC FACTOR; PLACEBO; PLASMID VECTOR; PROTEIN; RECOMBINANT NERVE GROWTH FACTOR; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN A; VIRUS VECTOR;

ANALGESIA; BLOOD VESSEL; CELL REGENERATION; CELL SURVIVAL; CLINICAL TRIAL; DIABETIC NEUROPATHY; DNA VECTOR; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; EDITORIAL; EXPRESSION VECTOR; GLYCEMIC CONTROL; HUMAN; IN VIVO GENE TRANSFER; LEG; LIPOSOMAL GENE DELIVERY SYSTEM; MICROVASCULAR ISCHEMIA; NERVE CELL; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PLACEBO EFFECT; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; SENSORY DYSFUNCTION; VIRAL GENE DELIVERY SYSTEM; GENE THERAPY; GENETICS; METHODOLOGY; NOTE;

DIABETIC NEUROPATHIES; GENE THERAPY; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65649111556     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21686     Document Type: Editorial

References (26)

1. Said G. Diabetic neuropathy-a review. Nat Clin Pract Neurol 2007;3:331-340.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
3. Martin CL, Albers J, Herman WH, et al; DCCT/EDIC Research Group. Neuropathy among the Diabetes Control and Complications Trial Cohort 8 years after trial completion. Diabetes Care 2006;29:340-344.
4. Ropper AH, Gorson KC, Gooch CL, et al. Vascular endothelial growth factor gene transfer for diabetic, polyneuropathy: A randomized, double-blinded trial. Ann Neuro 2009;65:386-393
5. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001;107:1083-1092.
6. Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 2001;107:1215-1218.
7. Apfel SC. Neurotrophic factors and diabetic peripheral neuropathy. Eur Neurol 1999;41(suppl 1):27-34.
8. Nigel A, Calcutt NA, Jolivalt CG, Fernyhough P. Growth factors as therapeutics for diabetic neuropathy. Curr Drug Targets 2008;9:47-59.
9. Fernyhough P, Diemel, LT, Hardy J. et al. Altered neurotro- phin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats. Eur J Neurosci 1995;7:1107-1110.
10. Schmidt, RE, Plurad, SB, Saffitz, et al. Retrograde axonal transport of 125I-nerve growth factor in rat ileal mesenteric nerves. Effect of streptozocin diabetes. Diabetes 1985;34:1230 -1240.
11. Hellweg R, Raivich G, Hartung HD, et al. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 1994;130: 24-30.
12. Mizisin AP, DiStefano PS, Liu X, et al. Decreased accumulation of endogenous brain-derived neurotrophic factor against constricting sciatic nerve ligatures in streptozotocin-diabetic and galactose-fed rats. Neurosci Lett 1999;263:149 -152.
13. Wuarin L, Guertin DM, Ishii DN. Early reduction in insulinlike growth factor gene expression in diabetic nerve. Exp Neurol 1994;130:106 -114.
14. Schmidt RE, Dorsey DA, Beaudet LN, Peterson RG. Analysis of the Zucker Diabetic Fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic auto- nomic neuropathy. Am J Pathol 2003;163:21-28.
15. Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998;51:695-702.
16. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000;284:2215-2221.
17. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002;50:393-413.
18. Wellmer A, Misra VP, Sharief MK, et al. A double-blind placebo-controlled clinical trial of recombinant human brain- derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J Peripher Nerv Syst 2001;6:204-210.
19. Fagerberg SE. Diabetic neuropathy, a clinical and histological study on the significance of vascular affection. Acta Med Scand Suppl 1959;345:1-97.
20. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44:1973-1988.
21. Tesfaye S, Harris N, Jakubowski JJ, et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 1993;36:1266 -1274.
22. Rosenstein JM, Mani N, Khaibullina A, Krum JM. Neurotro- phic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J Neurosci 2003; 23:11036 -11044.
23. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999;19: 5731-5740.
24. Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci 2000;12: 4243-4254.
25. Murakami T, Arai M, Sunada Y, Nakamura A. VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J Gene Med 2006;8:773-781.
26. Freedman SB, Vale P, Kalka C, et al. Plasma vascular endothe- lial growth factor (VEGF) levels after intramuscular and in- tramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther 2002;13:1595-1603.